Literature DB >> 24909734

Serum soluble urokinase plasminogen activator receptor in alcoholics: relation to liver disease severity, fibrogenesis, and alcohol use.

Heidi Tuomi1, Johanna Kultti, Joanna Danielsson, Päivikki Kangastupa, Kari Akerman, Onni Niemelä.   

Abstract

BACKGROUND AND AIM: Heavy alcohol consumption may lead to development of liver disease and the need for non-invasive parameters for detecting those at risk is widely acknowledged.
METHODS: We measured serum soluble urokinase-type plasminogen activator receptor (suPAR) levels from 63 patients with alcoholic liver disease (ALD), 57 heavy drinkers without apparent liver disease, and 39 controls who were either moderate drinkers or abstainers.
RESULTS: The highest serum suPAR concentrations were detected in patients with ALD (P < 0.001) showing high diagnostic accuracy in differentiating ALD patients from heavy drinkers without liver disease (area under curve 0.921, P < 0.001). Levels of suPAR correlated positively with serum markers of fibrogenesis (aminoterminal propeptide of type III procollagen and hyaluronic acid) (P < 0.001), with clinical (combined clinical and laboratory index P < 0.01) and morphological (combined morphological index P < 0.05) indices of liver disease severity and with the stage of fibrosis (P < 0.01). The suPAR concentrations were also elevated in heavy drinkers when compared with healthy controls (P < 0.001).
CONCLUSION: The data indicate that serum suPAR concentrations are increased as a result of heavy alcohol consumption and further with development of ALD, showing a good diagnostic performance in detecting those with liver disease. The association with the histological severity of ALD and correlation with fibrosis indicates potential of serum suPAR also as a prognostic marker in ALD.
© 2014 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  ethanol; fibrosis; liver; prognosis; suPAR

Mesh:

Substances:

Year:  2014        PMID: 24909734     DOI: 10.1111/jgh.12639

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  4 in total

Review 1.  Soluble Urokinase Receptor and Liver Disease.

Authors:  Changli Wei; Ke Zhu; Jochen Reiser
Journal:  Clin Liver Dis (Hoboken)       Date:  2019-12-20

2.  Soluble Urokinase Plasminogen Activator Receptor Levels Are Associated with Severity of Fibrosis in Patients with Primary Sclerosing Cholangitis.

Authors:  Burcin Özdirik; Martin Maibier; Maria Scherf; Jule Marie Nicklaus; Josephine Frohme; Tobias Puengel; Dirk Meyer Zum Büschenfelde; Frank Tacke; Tobias Mueller; Michael Sigal
Journal:  J Clin Med       Date:  2022-04-28       Impact factor: 4.964

3.  Risk factors associated with serum levels of the inflammatory biomarker soluble urokinase plasminogen activator receptor in a general population.

Authors:  Thomas H Haupt; Thomas Kallemose; Steen Ladelund; Line Jh Rasmussen; Christian W Thorball; Ove Andersen; Charlotta Pisinger; Jesper Eugen-Olsen
Journal:  Biomark Insights       Date:  2014-12-16

Review 4.  Biomarker-Based Approaches for Assessing Alcohol Use Disorders.

Authors:  Onni Niemelä
Journal:  Int J Environ Res Public Health       Date:  2016-01-27       Impact factor: 3.390

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.